Quantitative brain MRI was used to evaluate 18 RRMS patients and 10 age matched controls at baseline and 6 months. The study aimed to assess test-retest reproducibility in healthy controls, disease variability in the RRMS population, and sensitivity to disease progression of each MRI-derived parameter. The results will inform the selection of MRI measures to be used as biomarkers in future clinical trials. In addition, longitudinal multiparametric assessment of MS lesions may improve our understanding of different pathological components of such lesions (e.g. inflammation, demyelination, and iron accumulation) during disease progression.